Enrollment Completed for the SAD Part 1 of Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

drugs.com - 05/Sep 04:09

NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

MindBio advances world-first psychedelic microdosing clinical trials

themarketherald.ca - 29/Aug 14:44

MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

drugs.com - 03/Sep 20:09

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....

Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound

zacks.com - 28/Aug 17:18

LLY's single-dose vials are priced at least 50% lower than the list price of all other GLP-1 medicines for obesity.

ESC consensus statement highlights obesity's impact on cardiovascular disease

news.medical.net - 30/Aug 14:49

The ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at this year's ESC Congress (London, UK, 30 August to 2...

Pregnant Women Exposed To PFAS May Be At Risk For Obesity, Heart Disease Later In Life

eurasiareview.com - 05/Sep 22:12

Women with higher levels of per- and polyfluoroalkyl substances (PFAS) during pregnancy may experience long-term weight gain and heart problems...

Ocugen completes dosing in subjects with Stargardt disease in high dose cohort of phase 1/2 GARDian trial of OCU410ST, a modifier gene therapy

pharmabiz.com - 29/Aug 00:00

Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced...

Rubriques :

Enrollment Completed for the SAD Part 1 of Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Articles similaires

First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

MindBio advances world-first psychedelic microdosing clinical trials

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound

ESC consensus statement highlights obesity's impact on cardiovascular disease

Pregnant Women Exposed To PFAS May Be At Risk For Obesity, Heart Disease Later In Life

Ocugen completes dosing in subjects with Stargardt disease in high dose cohort of phase 1/2 GARDian trial of OCU410ST, a modifier gene therapy

Syneos Health: Research Nurse-Utretch, Netherlands

Syneos Health: Research Nurse-Bordeaux, France

Syneos Health: Research Nurse-Marseilles, France

Les derniers communiqués